EP 1481093 A4 20081001 - MODULATION OF TYPE IIbeta PHOSPHOINOSITIDE PHOSPHATE KINASE
Title (en)
MODULATION OF TYPE IIbeta PHOSPHOINOSITIDE PHOSPHATE KINASE
Title (de)
MODULATION DER PHOSPHOINOSITID-PHOSPHATKINASE TYP-IIbeta
Title (fr)
MODULATION DE LA PHOSPHOINOSITIDE PHOSPHATE KINASE DE TYPE II$G(B)
Publication
Application
Priority
- US 0303065 W 20030203
- US 35375802 P 20020201
Abstract (en)
[origin: WO03064451A2] The invention provides methods for modulating type IIbeta phosphoinisitide phosphate kinase PIPKIIbeta activity for treating PIPKIIbeta-associated disorders. The invention also provides methods of identifying candidate agents for treating PIPKIIbeta-associated disorders.
IPC 1-7
IPC 8 full level
A01K 67/027 (2006.01); A61K 31/155 (2006.01); A61K 31/198 (2006.01); A61K 31/427 (2006.01); A61K 31/4439 (2006.01); A61K 31/4453 (2006.01); A61K 31/64 (2006.01); A61K 31/7088 (2006.01); A61K 38/28 (2006.01); A61K 45/00 (2006.01); A61K 45/06 (2006.01); A61K 49/00 (2006.01); A61P 3/04 (2006.01); A61P 3/10 (2006.01); A61P 43/00 (2006.01); C12N 9/12 (2006.01); C12N 15/09 (2006.01); C12N 15/85 (2006.01); C12Q 1/02 (2006.01); C12Q 1/48 (2006.01); C12Q 1/68 (2006.01); G01N 33/15 (2006.01); G01N 33/50 (2006.01); G01N 33/53 (2006.01); G01N 33/573 (2006.01); G01N 37/00 (2006.01); A61K 38/00 (2006.01)
CPC (source: EP US)
A01K 67/0276 (2013.01 - EP US); A61K 49/0008 (2013.01 - EP US); A61P 3/04 (2017.12 - EP); A61P 3/10 (2017.12 - EP); A61P 43/00 (2017.12 - EP); C12N 9/1205 (2013.01 - EP US); C12N 15/8509 (2013.01 - EP US); C12Q 1/485 (2013.01 - EP US); G01N 33/573 (2013.01 - EP US); A01K 2217/075 (2013.01 - EP US); A01K 2227/105 (2013.01 - EP US); A01K 2267/0325 (2013.01 - EP US); A61K 38/00 (2013.01 - EP US)
Citation (search report)
- [A] WO 0000584 A2 20000106 - UNIV UTAH RES FOUND [US], et al
- See references of WO 03064451A2
Citation (examination)
- WO 9727847 A1 19970807 - MERCK & CO INC [US], et al
- US 6291172 B1 20010918 - DAVIS ROBERT E [US], et al
- RAPTIS S.A. ET AL: "Oral hypoglycemic agents: insulin secretagogues, alpha-glucosidase inhibitors and insulin sensitizers", EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY AND DIABETES, JOHANN AMBROSIUS BARTH, DE, vol. 09, no. SUPPL. 2, 1 January 2001 (2001-01-01), pages S265 - S287, XP008115734, ISSN: 0947-7349
Designated contracting state (EPC)
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT SE SI SK TR
DOCDB simple family (publication)
WO 03064451 A2 20030807; WO 03064451 A3 20030904; CA 2473990 A1 20030807; EP 1481093 A2 20041201; EP 1481093 A4 20081001; JP 2005516073 A 20050602; US 2006089320 A1 20060427
DOCDB simple family (application)
US 0303065 W 20030203; CA 2473990 A 20030203; EP 03735115 A 20030203; JP 2003564071 A 20030203; US 50299305 A 20050824